Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
8.20
0.00 (0.00%)
Jan 22, 2025, 4:00 PM EST - Market closed
Cogent Biosciences Employees
Cogent Biosciences had 164 employees as of December 31, 2023. The number of employees increased by 26 or 18.84% compared to the previous year.
Employees
164
Change (1Y)
26
Growth (1Y)
18.84%
Revenue / Employee
n/a
Profits / Employee
-$1,477,421
Market Cap
905.79M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 164 | 26 | 18.84% |
Dec 31, 2022 | 138 | 61 | 79.22% |
Dec 31, 2021 | 77 | 62 | 413.33% |
Dec 31, 2020 | 15 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
COGT News
- 4 hours ago - 3 Biotech Stocks With Notable Insider Buying - Seeking Alpha
- 4 days ago - Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data - Seeking Alpha
- 6 weeks ago - Why Is Cogent Biosciences Stock Trading Higher On Monday? - Benzinga
- 6 weeks ago - Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - GlobeNewsWire
- 7 months ago - Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 8 months ago - Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - GlobeNewsWire
- 8 months ago - Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting - GlobeNewsWire